Jianbin Mao

Jianbin Mao serves as the Director of Global Value & Access at Cerevel Therapeutics since April 2022, focusing on clinical trial endpoint recommendations, value evidence generation, and cross-functional team collaboration to enhance patient access and reimbursement. Prior experience includes the role of Director of Global Value and Access at Acceleron Pharma, where responsibility included real-world evidence (RWE) generation for sotatercept in pulmonary arterial hypertension. Jianbin Mao has also held positions at Merck as Associate Director of Outcomes Research, overseeing evidence generation strategies for HIV, and at Optum as Associate Director of Health Economics and Outcomes Research, executing RWE studies and fostering client relationships. Earlier roles include Director of Analysis at Proventys and Director of Analytics at IntrinsiQ, leading oncology market research and analytics initiatives. Academic training culminated in a PhD in Biopsychology from Stony Brook University.